Has Philip Lottinger received payments from drug or device companies?

Yes. Drug and device makers reported $3,324 in general payments to Philip Lottinger across 136 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Philip Lottinger did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Philip Lottinger come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Philip Lottinger

Psychiatric/Mental Health · Houma, LANPI 1013635937

Payments from drug & device makers

$3,324in general payments, 2019–2025

Across 136 payments — averaging $24.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

AbbVie$972
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$436
Neurocrine Biosciences, Inc.$331
Johnson & Johnson$331
Vanda Pharmaceuticals Inc.$249
Alkermes, Inc.$213
plus $793 from 12 others

What the payments were for

Food & beverage$3,324100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
AbbVie	40	$972
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)	11	$436
Neurocrine Biosciences, Inc.	16	$331
Johnson & Johnson	10	$331
Vanda Pharmaceuticals Inc.	10	$249
Alkermes, Inc.	10	$213
E.r. Squibb & Sons, L.L.C.	10	$153
Axsome Therapeutics, Inc.	6	$152
Otsuka America Pharmaceutical, Inc.	3	$143
Corium, LLC	5	$61
Supernus Pharmaceuticals, Inc.	3	$59
Teva Pharmaceuticals USA, Inc.	3	$50
Boston Scientific	2	$46
Merck	2	$43
Lundbeck LLC	2	$30
Indivior Inc.	1	$27
Braeburn Inc.	1	$16
Takeda Pharmaceuticals U.S.A., Inc.	1	$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,324 in reported general payments places this provider in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.

See all psychiatric/mental health providers in Louisiana →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
VraylarCariprazine Hcl	56	$90,463
RexultiBrexpiprazole	11	$18,472
TrintellixVortioxetine Hydrobromide	18	$9,708
Bupropion XlBupropion Hcl	94	$1,421
Quetiapine Fumarate	130	$1,130
Hydroxyzine Hcl	25	$961
Mirtazapine	69	$920
Oxcarbazepine	26	$801
Hydroxyzine Pamoate	62	$776
Aripiprazole	50	$726
Buspirone Hcl	68	$712
Trazodone Hcl	107	$695
Naltrexone Hcl	11	$457
Prazosin Hcl	49	$444
Duloxetine Hcl	35	$389

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

Company	Paid to this provider	Part D cost of their drugs
AbbVieVraylar	$972	$90,46356 claims
Otsuka America Pharmaceutical, Inc.Rexulti	$143	$18,47211 claims
Takeda Pharmaceuticals U.S.A., Inc.Trintellix	$14	$9,70818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 615 psychiatric/mental health providers in Louisiana.

Other psychiatric/mental health in Houma

Amanda EymardHouma$617K
Timothy PellegrinHouma$210K
Harry BrownHouma$9K
Amy LacoutureBaton Rouge$663K
Amber LittlefieldBroussard$225K
Melissa GuilbeauLafayette$122K
Kimberly ForcinelShreveport$92K
Sattaria DilksLake Charles$57K
Joe TaylorHammond$38K
Lecy AlbaradoScott$34K

See the full list for Louisiana →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →